For a Healthier Future
Central Texas Clinical Research
  
Welcome
About CTCR
Investigators
Studies
Contact Us
 
 


November 2008

Currently Enrolling HIV Studies


Treatment Naive Studies
  • Viramune Extended Release 400 mg daily vs Viramune 200 mg twice a day - 48 weeks
    Truvada will be added to each arm

Failing Regimen Studies

  • Dose confirming study of the safety, efficacy and tolerability of apricitabine versus lamivudine - 48 weeks
    For treatment-experienced HIV-1 infected patients with the M184V/I mutation in reverse transcriptase


Other HIV Studies

  • HIV-Associated Diarrhea - 24 weeks
    In this study, researchers are looking to see if an investigational medicine can help control HIV-associated diarrhea. Crofelemer is the investigational medicine being tested in this study. It comes from a common tree found in Central and South America that has been widely used within those cultures for its medicinal properties, including the treatment of diarrhea.





To inquire about any of these studies call us at
(512) 480-9660

or email: info@ctcrcorp.com

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Copyright © Central Texas Clinical Research 2003-2008. All rights reserved.